Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sagimet Biosciences (SGMT) Free Cash Flow (2023 - 2024)

Sagimet Biosciences (SGMT) has 2 years of Free Cash Flow data on record, last reported at -$11.0 million in Q4 2024.

  • For Q4 2024, Free Cash Flow fell 55.64% year-over-year to -$11.0 million; the TTM value through Dec 2024 reached -$42.4 million, down 78.55%, while the annual FY2025 figure was -$45.6 million, 7.58% down from the prior year.
  • Free Cash Flow reached -$11.0 million in Q4 2024 per SGMT's latest filing, up from -$19.6 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$3.9 million in Q3 2023 and bottomed at -$19.6 million in Q3 2024.